Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2017
A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with
Open access · bronzeAbstract readClinical Trial, Phase IIMulticenter Study
In one paragraph
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 2 pooled it
6.0field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- Prognostic value of FGFR1 expression and amplification in patients with HNSCC: A systematic review and meta-analysis.PloS one · 2021Pooled it
- Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin.European urology · 2020Pooled it
- FGFR3 oncogenic activation drives oxidative metabolic reprogramming in bladder cancer: a systems metabolomics approach.Communications biology · 2026Article
- Narrative Review of Potential Non-Surgical Treatments for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer.Journal of clinical medicine · 2026Review
- Bladder-sparing strategies for non-muscle-invasive bladder cancer after bacillus Calmette-Guérin failure: a systematic review.BMJ oncology · 2026Article
- [FGFR2/3 in urothelial carcinoma].Pathologie (Heidelberg, Germany) · 2024Article
- Experimental and New Approaches for Bladder Preservation in Intermediate and High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC).Research and reports in urology · 2024Review
- Targeted Therapy in Non-Muscle Invasive Bladder Cancer-Clinical Updates.Archives of pharmacology and therapeutics · 2024Article
- Landscape of targeted therapies for advanced urothelial carcinoma.Exploration of targeted anti-tumor therapy · 2024Review
- Article
- Review
- Fibroblast growth factor receptors as targets for anticancer therapy in cholangiocarcinomas and urothelial carcinomas.Heliyon · 2023Review
- BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: Current Treatment Landscape and Novel Emerging Molecular Targets.International journal of molecular sciences · 2023Review
- Tackling FGFR3-driven bladder cancer with a promising synergistic FGFR/HDAC targeted therapy.NPJ precision oncology · 2023Article
- A systematic review on the available treatment modalities for Bacillus Calmette-Guérin-unresponsive carcinoma in situ and tumors in patients who are ineligible for or decline radical cystectomy.SAGE open medicine · 2023Review
- A global method for fast simulations of molecular dynamics in multiscale agent-based models of biological tissues.iScience · 2022Article
- Non-muscle invasive bladder cancer biomarkers beyond morphology.Frontiers in oncology · 2022Review
- Fibroblast growth factor receptor fusions in cancer: opportunities and challenges.Journal of experimental & clinical cancer research : CR · 2021Review
- Inhibition of FGF-FGFR and VEGF-VEGFR signalling in cancer treatment.Cell proliferation · 2021Review
- Biomarker-Oriented Therapy in Bladder and Renal Cancer.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 7 institutions in 1 country.
Noah M HahnJohns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland. nhahn4@jhmi.edu.
Trinity J BivalacquaJohns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.
Ashley E RossJohns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.
George J NettoJohns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.
Alex BarasJohns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.
Jong Chul ParkJohns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.
Carolyn ChapmanJohns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.
Timothy A MastersonDepartment of Urology, Indiana University Simon Cancer Center, Indianapolis, Indiana.
Michael O KochDepartment of Urology, Indiana University Simon Cancer Center, Indianapolis, Indiana.
Richard BihrleDepartment of Urology, Indiana University Simon Cancer Center, Indianapolis, Indiana.
Richard S FosterDepartment of Urology, Indiana University Simon Cancer Center, Indianapolis, Indiana.
Thomas A GardnerDepartment of Urology, Indiana University Simon Cancer Center, Indianapolis, Indiana.
Liang ChengDepartment of Pathology and Laboratory Medicine, Indiana University Simon Cancer Center, Indianapolis, Indiana.
David R JonesDepartment of Clinical Pharmacology, Indiana University Simon Cancer Center, Indianapolis, Indiana.
Kyle McElyeaDepartment of Pathology and Laboratory Medicine, Indiana University Simon Cancer Center, Indianapolis, Indiana.
George E SanduskyDepartment of Pathology and Laboratory Medicine, Indiana University Simon Cancer Center, Indianapolis, Indiana.
Timothy BreenHoosier Cancer Research Network, Indianapolis, Indiana.
Ziyue LiuIndiana University Department of Biostatistics, Schools of Public Health and Medicine, Indianapolis, Indiana.
Costantine AlbanyDivision of Hematology and Oncology, Indiana University Simon Cancer Center, Indianapolis, Indiana.
Marietta L MooreDivision of Hematology and Oncology, Indiana University Simon Cancer Center, Indianapolis, Indiana.
Rhoda L LomanDivision of Hematology and Oncology, Indiana University Simon Cancer Center, Indianapolis, Indiana.
Angela ReedDivision of Hematology and Oncology, Indiana University Simon Cancer Center, Indianapolis, Indiana.
Scott A TurnerDepartment of Pathology and Laboratory Medicine, Geisel School of Medicine at Dartmouth, Dartmouth Hitchcock Medical Center and Norris Cotton Cancer Center, Lebanon, New Hampshire.
Francine B De AbreuDepartment of Pathology and Laboratory Medicine, Geisel School of Medicine at Dartmouth, Dartmouth Hitchcock Medical Center and Norris Cotton Cancer Center, Lebanon, New Hampshire.
Torrey GallagherDepartment of Pathology and Laboratory Medicine, Geisel School of Medicine at Dartmouth, Dartmouth Hitchcock Medical Center and Norris Cotton Cancer Center, Lebanon, New Hampshire.
Gregory J TsongalisDepartment of Pathology and Laboratory Medicine, Geisel School of Medicine at Dartmouth, Dartmouth Hitchcock Medical Center and Norris Cotton Cancer Center, Lebanon, New Hampshire.
Elizabeth R PlimackDepartment of Hematology and Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Richard E GreenbergDepartment of Urology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Daniel M GeynismanDepartment of Hematology and Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Indiana University Health · USAmerican Urological Association · USDartmouth–Hitchcock Medical Center · USFox Chase Cancer Center · USSidney Kimmel Comprehensive Cancer Center · USHoosier Cancer Research Network (United States) · USIndiana University – Purdue University Indianapolis · US
Funding
Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6MTumor Microenvironment and Metastasis ProgramP30CA082709 · NCI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI Jun Wan · 1999 to 2026
$59.3MNCI NIH HHS P30 CA006973NCI NIH HHS P30 CA082709
Abstract
PubMed holds no abstract for this paper.
Indexed as
AgedBenzimidazolesCarcinoma, Transitional CellFemaleGene Expression Regulation, NeoplasticHumansImmunohistochemistryMaleMiddle AgedMutationMycobacterium bovisQuinolonesReceptor, Fibroblast Growth Factor, Type 3Urinary Bladder NeoplasmsUrothelium4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-oneBenzimidazolesFGFR3 protein, humanQuinolonesReceptor, Fibroblast Growth Factor, Type 3
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.